3D LifePrints Achieves ISO 13485:2016 Certification

3D LifePrints, a leading 3D technology company providing innovative solutions to the medical sector, announced today that it has achieved ISO 13485:2016 certification for its Quality Management System (QMS).

3D LifePrints notes the certification enables 3D LifePrints to expand its industry-leading Point-of-Care model by launching a new range of patient-specific sterilizable Surgical Guides and Anatomical Models, whilst continuing to deliver its existing custom-made medical devices.

The certification is underpinned by 3D LifePrints’ Digital Platform EmbedmedTM. It includes the design and manufacture of sterilizable devices within a Controlled Environment in one of 3D LifePrints’ embedded Hubs.  This innovation brings the timeline for delivery of these types of devices down from weeks to days.

An internationally recognized standard of excellence, ISO 13485:2016 is a stringent set of guidelines for the medical device industry. The standard ensures that an organization maintains its quality and compliance levels specific to the design, manufacture, and distribution of medical devices.

Henry Pinchbeck, CEO says: “It has long been our goal to standardize our processes by adherence to this internationally recognized standard. The formal certification of our QMS opens up considerable market opportunities for the business and is a clear signal to our customers of the importance we attach to Quality Assurance and Patient Care.”

3D LifePrints’ primary focus is the supply of patient-specific 3D printed medical devices to organizations including hospitals, universities, and medical device manufacturers. Their current key Hubs include Alder Hey Children’s Hospital in Liverpool, Nuffield Orthopaedic Centre in Oxford, Wrightington Hospital in Greater Manchester, and Leeds General Infirmary.

The company operates a unique operating model where the products are delivered AA Service from embedded Hubs within host institutions. The Point-of-Care service includes bio-medical engineers; a range of advanced 3D printing hardware and a suite of software. The embedded nature enables the host institution to enjoy all of the benefits of having an ‘in-house’ service including ease of access to an engineer and immediate delivery of the devices.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”